Navigation Links
Safety of Labor-Delaying Drugs Questioned
Date:3/6/2009

The dilemma, researchers say, is whether or not to treat at all

FRIDAY, March 6 (HealthDay News) -- Certain drugs used to delay preterm labor can cause serious complications in women, a European study finds.

Doctors use tocolytic drugs to delay labor for up to 48 hours. In this way, they gain time to allow steroids to hasten fetal lung development. These delays also enable the expectant mother to be transferred to a medical facility with a neonatal intensive care unit, according to background information in the study.

The most widely used tocolytic drugs include beta agonists and nifedipine (which relax smooth muscles, including the uterus), and atosiban and indometacin (which inhibit hormones involved in labor), according to the study. However, the use of these drugs is controversial, because it's not clear whether tocolysis is safe for both mother and baby.

The researchers analyzed the rate of serious complications in 1,920 women treated with tocolytic drugs for preterm labor at 28 hospitals in the Netherlands and Belgium. Atosiban was the most commonly used drug (42 percent), followed by nifedipine (34 percent), beta agonists (14 percent), and indometacin (8 percent).

The overall incidence of adverse effects was 0.7 percent, but combined or single treatment with a beta agonist led to a higher incidence of serious drug reactions. There were no reports of serious reactions when women received atosiban or indometacin.

Combined or single treatment with beta agonists should be discouraged, concluded the researchers. They also recommended further trials to test the safety and effectiveness of nifedipine and atosiban.

In an accompanying editorial, the researchers said their study is a reminder that the decision to use tocolysis shouldn't be taken lightly.

"After 30 years of research, we still do not know whether tocolysis benefits the fetus, so the choice of which drug to use remains a secondary question. The real dilemma is whether or not we should treat at all," they wrote. The long-held belief that "keeping the baby inside longer must be a good thing" needs to be reevaluated, they said.

The study was published March 6 online in the BMJ.

A study released last year found that nifedipine was no more effective than placebo at preventing preterm labor. The U.S. study, which included 71 women, was published in the journal Obstetrics & Gynecology.

More information

The U.S. National Institute on Child Health and Human Development has more about preventing preterm birth.



-- Robert Preidt



SOURCE: BMJ, news release, March 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. AdvaMed Available for Comment on Medical Device Safety Act
2. AdvaMed Response to the Medical Device Safety Act
3. bioPoint(TM) PID Wristband Software Improves Patient Identification Accuracy and Safety
4. New Esco White Papers Document Hydrogen Peroxide Decontamination of Biological Safety Cabinets
5. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
6. Zebra Technologies Introduces New Soft Infant Wristbands for Improved Safety and Comfort
7. Travel Safety Can Be a Passport to Good Health
8. Main U.S. Toxics Law Failing to Ensure Safety of Thousands of Chemicals
9. Johns Hopkins safety team works to eliminate bloodstream infections in the nation and the world
10. Governor Rendell Forms Food Safety Council to Protect Public Health, Food Supply
11. Switch to Daylight Savings Time Will Launch First Annual Sedation Dentistry Safety Week Hosted by DOCS Education
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Safety of Labor-Delaying Drugs Questioned
(Date:2/27/2017)... ... ... not your typical author. She went from working as a movie extra on Bill Murray’s ... she isn’t swimming as a performing mermaid. , Her book isn’t typical either. In Carothers’ ... comedic look at the dysfunctions of God’s family, before Lucifer was sent to hell. ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed ... that despite scientific studies, the Center for Disease Control ( CDC ) and Infectious ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... clinic serving San Francisco and environs, is proud to announce an upgrade to ... information on the upgraded Yelp page on topics as diverse as Platelet Rich ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... and reporting for healthcare organizations. This comprehensive and customizable solution empowers StaffBridge ... StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting data, ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017 A recent research report published by ... alone is expected to reach a value of $55.8 billion by ... with 28 states have legalized marijuana for medical uses. In 2016, ... , North Dakota , Ohio ... use the drug in medical applications such as chemotherapies and pain ...
(Date:2/27/2017)... , Feb 27, 2017 Period October – December 2016 ... Operating result amounted to SEK -16.4 (-6.4) million Result ... share (-0.22) before and after dilution Cash flow from operating ... ... SEK 0.4 (0.4) million Operating result amounted to SEK -39.5 ...
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Medicine Technology: